Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial

Background: Although biliary tract cancer (BTC) has a very aggressive nature, some patients maintain a relatively good performance status after failure with first-line treatment of gemcitabine plus cisplatin (GC). Thus, tolerable, feasible, and useful second-line treatments are needed for these pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer
Main Authors: Kim, Seung Tae, Oh, Sung Yong, Lee, Jeeyun, Kang, Jung Hun, Lee, Hyun Woo, Lee, Myung Ah, Sohn, Byeong Seok, Hong, Ji Hyong, Park, Young Suk, Park, Joon Oh, Lim, Ho Yeong
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2019
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6856733/
https://ncbi.nlm.nih.gov/pubmed/31772650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.37610
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados